Skip to main content

PROMs for Systemic Lupus Erythematosus

  • Chapter
  • First Online:
Patient Reported Outcome Measures in Rheumatic Diseases

Abstract

Patients with active Systemic Lupus Erythematosus (SLE) experience a large variation of symptoms and manifestations. The symptoms and manifestations of SLE impact the patients’ health-related quality of life (HRQoL). Many of the patients’ SLE symptoms are not always adequately captured by objective clinical outcome measures or laboratory assessments alone. Therefore in addition to well-established clinical outcome measures used in clinical practice, the patient perspective should be captured through patient reported outcome measures (PROMs). Key concepts/domains derived from a recently developed conceptual model published by Holloway et al. (Qual Life Outcomes. 2014;12:116) are the basis for the recommendations of PROMs. Recommendations for PROMs to apply in clinical practice are based on the face and content validity as well as psychometric properties of each of the PROMs. In the conceptual model, fatigue, pain, and emotional well-being/depression were identified as key domains impacting the lives of patients with SLE. Appropriate PROMs to use in clinical practice capturing the key domains are the Functional Assessment of Chronic Illness Therapy—Fatigue scale (FACIT-Fatigue), Brief Pain Inventory (BPI-SF), and Hospital Anxiety and Depression Scale (HADS). In addition the generic HRQoL measure Short Form (36 item) Health Survey version 2 (SF-36v2) and the disease-specific HRQoL measure LupusQoL can be applied in clinical practice. It might be favorable in standard clinical practice to consider including one cohesive PROM for the assessment of patient reported key symptoms and impacts in SLE, however, further research and validation studies are needed. PROMs capturing key symptoms of SLE such as fatigue, pain, and HRQoL supplement objective clinical outcome measures and laboratory assessments providing clinicians with a valuable patient perspective on the impact of SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis. 2006;1:6.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jolly M, Pickard AS, Wilke C, Mikolaitis RA, Teh LS, McElhone K, Fogg L, Block J. Lupus-specific health outcome measure for US patients: the LupusQoL-US version. Ann Rheum Dis. 2010;69:29–33.

    Article  CAS  PubMed  Google Scholar 

  3. Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, Højbjerre L, Strandberg-Larsen M, Bekker Hansen B. Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance. Health Qual Life Outcomes. 2014;12:116.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Beckerman NL. Living with lupus: a qualitative report. Soc Work Health Care. 2011;50:330–43.

    Article  PubMed  Google Scholar 

  5. McElhone K, Abbott J, Gray J, Williams A, Teh LS. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus. 2010;19:1640–7.

    Article  CAS  PubMed  Google Scholar 

  6. Robinson J, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res. 2010;62:266–73.

    Article  Google Scholar 

  7. Schneider M, Schmeding A, Carnarius H, Ager M, McWade V. Systemic lupus erythematosus (SLE): understanding the burden. Value Health. 2010;13:A470.

    Article  Google Scholar 

  8. Yee CS, McElhone K, Teh LS, Gordon C. Assessment of disease activity and quality of life in systemic lupus erythematosus—new aspects. Best Pract Res Clin Rheumatol. 2009;23:457–67.

    Article  PubMed  Google Scholar 

  9. Aberer E. Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus. Lupus. 2010;19:1118–24.

    Article  CAS  PubMed  Google Scholar 

  10. Strand V, Galateanu C, Pushparajah DS, Nikai E, Sayers J, Wood R, van Vollenhoven RF. Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey. Lupus. 2013;22:819–26.

    Article  CAS  PubMed  Google Scholar 

  11. Pettersson S, Lovgren M, Eriksson LE, Moberg C, Svenungsson E, Gunnarsson I, Henriksson EW. An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life. Scand J Rheumatol. 2012;41:383–90.

    Article  CAS  PubMed  Google Scholar 

  12. Gallop K, Nixon A, Swinburn P, Sterling KL, Naegeli AN, Silk ME. Development of a conceptual model of health-related quality of life for systemic lupus erythematosus (SLE) from the patients’ perspective. Lupus. 2012;21:934–43.

    Article  CAS  PubMed  Google Scholar 

  13. Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis Care Res. 2007;57:1348–57.

    Article  Google Scholar 

  14. Cleanthous S, Tyagi M, Isenberg DA, Newman SP. What do we know about self-reported fatigue in systemic lupus erythematosus? Lupus. 2012;21:465–76.

    Article  CAS  PubMed  Google Scholar 

  15. Ramsey-Goldman R, Rothrock N. Fatigue in systemic lupus erythematosus and rheumatoid arthritis. PM R. 2010;2:384–92.

    Article  PubMed  Google Scholar 

  16. Mattsson M, Moller B, Stamm T, Gard G, Bostrom C. Uncertainty and opportunities in patients with established systemic Lupus Erythematosus: a qualitative study. Musculoskeletal Care. 2012;10:1–12.

    Article  CAS  PubMed  Google Scholar 

  17. Kosinski M, Gajria K, Fernandes AW, Cella D. Qualitative validation of the FACIT-fatigue scale in systemic lupus erythematosus. Lupus. 2013;22:422–30.

    Article  CAS  PubMed  Google Scholar 

  18. Danoff-Burg S, Friedberg F. Unmet needs of patients with systemic lupus erythematosus. Behav Med. 2009;35:5–13.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yazdany J, Yelin E. Health-related quality of life and employment among persons with systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2010;36:15–32.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, Veale DJ. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009;68:196–200.

    Article  CAS  PubMed  Google Scholar 

  21. Robinson M, Sheets CS, Currie LM. Systemic lupus erythematosus: a genetic review for advanced practice nurses. J Am Acad Nurse Pract. 2011;23:629–37.

    Article  PubMed  Google Scholar 

  22. Johnsson PM, Sandqvist G, Bengtsson A, Nived O. Hand function and performance of daily activities in systemic lupus erythematosus. Arthritis Rheum. 2008;59:1432–8.

    Article  Google Scholar 

  23. Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, Goetzel RZ. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med. 2009;51:66–79.

    Article  PubMed  Google Scholar 

  24. Zhu TY, Tam LS, Li EK. The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects. Expert Rev Pharmacoecon Outcomes Res. 2012;12:53–69.

    Article  CAS  PubMed  Google Scholar 

  25. Zhu TY, Tam LS, Li EK. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2011;63:751–60.

    Article  Google Scholar 

  26. Yelin E, Katz P. Introduction to special section: cost and social and psychological impact of rheumatic diseases. Arthritis Rheum. 2008;59:457.

    Article  PubMed  Google Scholar 

  27. Zhu TY, Tam LS, Lee VWY, Lee KKC, Li EK. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum. 2009;61:1159–67.

    Article  PubMed  Google Scholar 

  28. Aghdassi E, Zhang W, St. Pierre Y, Clarke AE, Morrison S, Peeva V, Landolt-Marticorena C, Su J, Reich H, Scholey J, Herzenberg A, Pope JE, Peschken C, Lunnet Canios I, Wither JE, Fortin PR. Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol. 2011;38:658–66.

    Article  PubMed  Google Scholar 

  29. Strand V, Chu AD. Measuring outcomes in systemic lupus erythematosus clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2011;11:455–68.

    Article  PubMed  Google Scholar 

  30. Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1, e000031.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Lai JS, Beaumont JL, Ogale S, Brunetta P, Cella D. Validation of the functional assessment of chronic illness therapy-fatigue scale in patients with moderately to severely active systemic lupus erythematosus, participating in a clinical trial. J Rheumatol. 2011;38:672–9.

    Article  PubMed  Google Scholar 

  32. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936–9.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–9.

    PubMed  Google Scholar 

  34. Ozel F, Argon G. The effects of fatigue and pain on daily life activities in systemic lupus erythematosus. European J Internal Med. 2011;22:S70.

    Article  Google Scholar 

  35. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1(3):277–99.

    Article  CAS  PubMed  Google Scholar 

  36. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30(2):191–7.

    Article  CAS  PubMed  Google Scholar 

  37. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–38.

    CAS  PubMed  Google Scholar 

  38. Cleeland CS. The brief pain inventory: user guide. 2009. 63 p. http://www.mdanderson.org/education-and-research/departments-programs-andlabs/departments-and-divisions/symptom-research/symptom-assessmenttools/BPI_UserGuide.pdf.

  39. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994;330(9):592–6.

    Article  CAS  PubMed  Google Scholar 

  40. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims. Silver Spring, MD: Food and Drug Administration; 2009.

    Google Scholar 

  41. Atkinson TM, Rosenfeld BD, Sit L, Mendoza TR, Fruscione M, Lavene D, Shaw M, Li Y, Hay J, Cleeland CS, Scher HI, Breitbart WS, Basch E. Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Pain Symptom Manage. 2011;41(3):558–65.

    Article  PubMed  Google Scholar 

  42. Daut RL, Cleeland CS, Flannery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain. 1983;17(2):197–210.

    Article  CAS  PubMed  Google Scholar 

  43. Naegeli AN, Tomaszewski EL, Al Sawah S. Psychometric validation of the Brief Pain Inventory-Short Form in patients with systemic lupus erythematosus in the United States. Lupus. 2015;24:1377–83.

    Article  CAS  PubMed  Google Scholar 

  44. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.

    Article  CAS  PubMed  Google Scholar 

  45. Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2002;1:29.

    Article  Google Scholar 

  46. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale-A review of validation data and clinical results. J Psychosom Res. 1997;42:17–41.

    Article  CAS  PubMed  Google Scholar 

  47. Garris CP, Oglesby AK. Assessment of health care resource utilization by level of flare severity in patients with systemic lupus erythematosus (SLE) in the managed care setting. J Manag Care Pharm. 2011;17:552.

    Google Scholar 

  48. QualityMetric Inc. User’s manual for the SF-36v2 health survey. 3rd ed. 2011. http://www.qualitymetric.com/WhatWeDo/ManualsUserGuides/UsersManualfortheSF36v2HealthSurvey/tabid/328/Default.aspx.

  49. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Beaumont JLLJ, Cella D, Brunetta P, Ogale S. Validation of the SF-36 in patients with systemic lupus erythematosus (SLE). Arthritis Rheum. 2009;60:296.

    Google Scholar 

  51. Busija L, Pausenberger E, Haines TP, Haymes S, Buchbinder R, Osborne RH. Adult measures of general health and health-related quality of life: Medical Outcomes Study Short Form 36-Item (SF-36) and Short Form 12-Item (SF-12) Health Surveys, Nottingham Health Profile (NHP), Sickness Impact Profile (SIP), Medical Outcomes Study Short Form 6D (SF-6D), Health Utilities Index Mark 3 (HUI3), Quality of Well-Being Scale (QWB), and Assessment of Quality of Life (AQOL) [abstract]. Arthritis Care Res. 2011;63:S383–412.

    Article  Google Scholar 

  52. McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, Peers K, Isenberg D, Ferenkeh-Koroma A, Griffiths B, Akil M, Maddison P, Teh L-S. Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. Arthritis Care Res. 2007;57:972–9.

    Article  Google Scholar 

  53. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  54. Food and Drug Administration. Guidance for industry: systemic lupus erythematosus—developing medical products for treatment. 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf.

  55. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus, cutaneous lupus and lupus nephritis (draft). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139615.pdf.

  56. El Miedany Y, El Gaafary M, El Yassaki A, Ahmed I, Youssef S, Hegazi MO, Palmer D. Incorporating patient reported outcome measures in clinical practice: development and validation of a PROMs questionnaire for SLE. Ann Rheum Dis. 2013;72 Suppl 3:484.

    Google Scholar 

  57. Jolly M, Garris CP, Mikolaitis RA, Jhingran PM, Dennis G, Wallace DJ, Clarke A, Dooley MA, Parke A, Strand V, Alárcon GS, Kosinski M. Development and validation of the Lupus Impact Tracker: a patient-completed tool for clinical practice to assess and monitor the impact of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2014;66(10):1542–50.

    Article  Google Scholar 

  58. Ruperto N, Hanrahan LM, Alarcon GS, Belmont HM, Brey RL, Brunetta P, Buyon JP, Costner MI, Cronin ME, Dooley MA, Filocamo G, Fiorentino D, Fortin PR, Franks Jr AG, Gilkeson G, Ginzler E, Gordon C, Grossman J, Hahn B, Isenberg DA, Kalunian KC, Petri M, Sammaritano L, Sánchez-Guerrero J, Sontheimer RD, Strand V, Urowitz M, von Feldt JM, Werth VP, Merrill JT. International consensus for a definition of disease flare in lupus. Lupus. 2011;20:453–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Brian Bekker Hansen .

Editor information

Editors and Affiliations

Appendices

Appendix 1: FACIT-Fatigue is presented with permission from the copyright holder. Potential users

Potential users should go to http://www.facit.org/FACITOrg and contact copyright holder for permission before using FACIT-Fatigue in studies and clinical practice.

FACIT Fatigue Scale (Version 4)

Below is a list of statements that other people with your illness have said are important. Please circle or mark one number per line to indicate your response as it applies to the past 7 days.

  

Not at all

A little bit

Some-what

Quite a bit

Very much

HI7

I feel fatigued

0

1

2

3

4

HI12

I feel weak all over

0

1

2

3

4

An1

I feel listless (washed out)

0

1

2

3

4

An2

I feel tired

0

1

2

3

4

An3

I have trouble starting things because I am tired

0

1

2

3

4

An4

I have trouble finishing things because I am tired

0

1

2

3

4

An5

I have energy

0

1

2

3

4

An7

I am able to do my usual activities

0

1

2

3

4

An8

I need to sleep during the day

0

1

2

3

4

An12

I am too tired to eat

0

1

2

3

4

An14

I need help doing my usual activities

0

1

2

3

4

An15

I am frustrated by being too tired to do the things I want to do

0

1

2

3

4

An16

I have to limit my social activity because I am tired

0

1

2

3

4

Appendix 2: Brief Pain Inventory—Short Form

BPI-SF is presented with permission from the copyright holder. Potential users should go to www.mdanderson.org/departments/prg and contact copyright holder for permission before using BPI-SF in studies and clinical practice.

figure a
figure b

Appendix 3: LupusQoL

LupusQoL is presented with permission from the copyright holders. Anyone running a commercially funded study must obtain a license for the LupusQoL and pay the license fee. Use is free for noncommercially funded studies but copyright holders requires that researchers contact the licensors for permission before using to ensure that researchers use the professionally developed and validated translations only.

Potential users should go to www.lupusqol.com for more information on using LupusQoL in studies and clinical practice.

figure c
figure d
figure e
figure f

Appendix 4: Multidimensional Questionnaire for Patient Reported Outcome Measures—SLE

figure g
figure h

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Hansen, B.B., Højbjerre, L. (2016). PROMs for Systemic Lupus Erythematosus. In: El Miedany, Y. (eds) Patient Reported Outcome Measures in Rheumatic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-32851-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32851-5_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32849-2

  • Online ISBN: 978-3-319-32851-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics